⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31741797 | 0.84 | — | — | |
| SCHEMBL107536 | 0.84 | — | — | |
| SCHEMBL7877503 | 0.84 | — | — | |
| Bromide SCHEMBL6350036 | 0.82 | — | — | |
| Methyl Alcohol SCHEMBL17200864 | 0.80 | — | — | |
| Bicarbonate SCHEMBL997095 | 0.75 | MAPK1 (0.32) | — | |
| SCHEMBL10727948 | 0.75 | — | — | |
| SCHEMBL9847841 | 0.73 | — | — | |
| SCHEMBL8965969 | 0.71 | — | — | |
| SCHEMBL4273373 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4461734-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-4480953-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | claimed |
| CN-105451735-B | azetidine estrogen receptor modulators and uses thereof | 西拉根制药公司 | 2019-01-11 | — | — | CN | claimed |
| EP-4747387-A1 | COAGULATION FACTOR XI-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-2542221-B1 | CONCENTRATED PROTEIN FORMULATIONS | CYTODYN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104812-A1 | RAB27 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| EP-3601291-B1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122029186-A | Human growth hormone receptor antagonists and methods of use thereof | OPKO生物科学有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125356-A1 | TREATMENT OF LEISHMANIASIS | THE UNIV OF DURHAM (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12611383-B1 | Pharmaceutical compositions for treating MCT8 deficiency | RARE THYROID THERAPEUTICS INTERNATIONAL AB (SE) | 2026-04-28 | — | — | US | disclosed |
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | COGMOTIV FLEXCO (AT) | 2026-04-28 | — | — | US | disclosed |
| EP-1200444-B1 | NOVEL XANTHONE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENT | ZENTARIS GMBH (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-6403636-B1 | ISOLATION OF NOVEL XANTHONE NATURAL PRODUCT SOOTEPENSEONE FROM DASYMASCHALON SOOTEPENSE CRAIB, ANNONACEAE; ANTICANCER AGENT | ZENTARIS AG (DE) | 2002-06-11 | — | — | US | disclosed |
| EP-1200444-A1 | NOVEL XANTHONE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENT | Zentaris AG (DE) | 2002-05-02 | — | — | EP | disclosed |
| EP-1149072-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2001002408-A1 | NOVEL XANTHONE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENT | ZENTARIS AG (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065210-A1 | Novel xanthone compounds, their preparation and use as medicament | ASTA Medica Aktiengesellschaft (DE) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000037436-A1 | SULFONAMIDE HYDROXAMATES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| US-5837787-A | ACTIVATED CYCLOPENTADIENYL GROUP-4 TRANSITION-METAL CATALYST SYSTEM | EXXON CHEMICAL PATENTS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0340645-A1 | Formyl-Trimethylbicyclo(2,2,2)oct-7-ene Isomers | Henkel Kommanditgesellschaft auf Aktien (DE) | 1989-11-08 | — | — | EP | disclosed |